Kelledy Manson joined Neon as the company’s vice president of product development in 2015. She has nearly 25 years of experience in the biopharmaceutical industry, having been involved in all aspects of development in addition to program and alliance management.
Prior to Neon, Kelledy held leadership roles at a number of companies including, most recently, serving as vice president of alliance and program management at Epizyme. Prior to joining Epizyme, Kelledy served as vice president of product development at Adnexus, which was acquired by Bristol-Myers Squibb, where she led the development of novel protein therapeutics called AdnectinsTM. At Adnexus, she served as vice president of product development, leading the development of novel protein therapeutics called Adnectins. Prior to joining Adnexus, she was a program executive and senior director of bioanalytical chemistry at Therion Biologics, where she was responsible for leading the development of a first-in-class novel prostate cancer vaccine from early discovery through successful proof of concept Phase 2 clinical studies. Kelledy began her biopharmaceutical career at TSI Corporation and Genzyme Transgenics, where she was director of immunology and managed a multimillion-dollar global National Institutes of Health contract to evaluate novel human immunodeficiency virus vaccine strategies.
Kelledy holds a B.S. in medical technology from Michigan State University and a master’s degree in biology from Worcester Polytechnical Institute.